NICE NG89 recommendations for extended pharmacological thromboprophylaxis - is it justified and is it cost effective: a rebuttal from the British Society for Haematology.

Lester, Will; Gomez, Keith; Shapiro, Susie; Dabhi, Keval; Laffan, Mike

Lester, Will; Gomez, Keith; Shapiro, Susie; Dabhi, Keval; Laffan, Mike.

Afiliação

Lester W; Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Gomez K; Katherine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK.
Shapiro S; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Dabhi K; Health Informatics, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Laffan M; Department of Haematology, Imperial College Academic Health Sciences Centre, Hammersmith Hospital, London, UK.

Br J Haematol ; 186(5): 790-791, 2019 09.

Article em En | MEDLINE | ID: mdl-31168789

Assuntos

Anticoagulantes/uso terapêutico; Anticoagulantes/economia; Análise Custo-Benefício; Humanos; Reino Unido; Tromboembolia Venosa/prevenção & controle

Palavras-chave

NICE; guidelines; thromboprophylaxis; venous thromboembolism

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticoagulantes Tipo de estudo: Health_economic_evaluation Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google